Management of enteric fever with amdinocillin.
Twenty-six patients with enteric fever treated with amdinocillin and/or its pivaloyloxymethyl ester in 1975 to 1978 were compared with 21 patients with enteric fever treated with trimethoprim-sulfamethoxazole in 1972 to 1974. Diagnosis was based on clinical illness and isolation of Salmonella typhi or S. paratyphi A/B from blood cultures or stool cultures. The dosage of pivamdinocillin in adults was 400 to 800 mg, every 6 hours, for 10 to 16 days; dosage in children was half this amount for 11 to 15 days. Of the 21 patients treated with trimethoprim-sulfamethoxazole, 18 (86 percent) showed a satisfactory clinical response; 13 of these 18 had negative stools immediately after therapy, and two more were negative at the time of discharge (total: 83 percent). Mean hospital stay of these patients was 34.5 days. Of the 26 patients treated with amdinocillin, 23 showed a satisfactory clinical response; 20 of those responding clinically were still excreting the causative organism at the end of therapy; seven of the group remained as convalescent patients who continued to excrete the causative organism in feces at the time of discharge. Mean hospital stay was 43 days. The results of initial trials of amdinocillin and ampicillin in combination suggest that such therapy may be preferable to use of amdinocillin alone, although the excretion of the causative organism during convalescence has not been adequately assessed.
D000293:Adolescent; D000328:Adult; D000560:Amdinocillin / Q000009:adverse effects / Q000627:therapeutic use*; D000561:Amdinocillin Pivoxil / Q000009:adverse effects / Q000627:therapeutic use; D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use; D001831:Body Temperature / Q000187:drug effects; D002648:Child; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D010397:Penicillanic Acid / Q000627:therapeutic use*; D012008:Recurrence; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000627:therapeutic use; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014435:Typhoid Fever / Q000188:drug therapy*
D004338:Drug Combinations; D000561:Amdinocillin Pivoxil; D000667:Ampicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D010397:Penicillanic Acid; D014295:Trimethoprim; D013420:Sulfamethoxazole; D000560:Amdinocillin